Filing Details
- Accession Number:
- 0001593968-20-000622
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-04 16:38:57
- Reporting Period:
- 2020-03-02
- Accepted Time:
- 2020-03-04 16:38:57
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1771917 | Karuna Therapeutics Inc. | KRTX | Pharmaceutical Preparations (2834) | 270605902 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1777631 | K. Stephen Brannan | 33 Arch St Ste 3110 Boston MA 02110-1424 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-03-02 | 2,500 | $5.45 | 5,000 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2020-03-02 | 7,728 | $7.27 | 12,728 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-03-02 | 7,728 | $86.55 | 5,000 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Karuna Therapeutics, Inc. Common Stock | Option (right to buy) | Disposition | 2020-03-02 | 2,500 | $0.00 | 2,500 | $5.45 |
Karuna Therapeutics, Inc. Common Stock | Option (right to buy) | Disposition | 2020-03-02 | 7,728 | $0.00 | 7,728 | $7.27 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
76,557 | 2018-03-01 | 2027-06-02 | No | 4 | M | Direct |
55,861 | 2019-02-08 | 2028-08-09 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.